Treatment of Early Stage Hormone Receptor Positive Breast Cancer

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Treatment strategies for early-stage hormone receptor positive / human epidermal receptor 2 negative (HR+/HER2-) breast cancer comprise definitive local therapy (primary surgical management of the breast and axilla with or without adjuvant radiation), and adjuvant endocrine therapy with or without chemotherapy
  • Nearly all patients with early-stage, HR+ breast cancers should be considered as candidates for adjuvant endocrine therapy
  • Conversely, adjuvant chemotherapy is considered only in a subgroup of patients with HR+/HER2- early breast cancer, based on the predicted risk for recurrence; the expected benefit from chemotherapy; and patient-specific factors, such as comorbidities.
  • In very select cases, neoadjuvant endocrine therapy or chemotherapy may be an option for patients with early-stage HR+ disease prior to surgery.
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

1 thought on “Treatment of Early Stage Hormone Receptor Positive Breast Cancer”

  1. Thanks for the valuable information on treatment strategies for early-stage HR+/HER2- breast cancer, and highlighting the effectiveness of adjuvant endocrine therapy as a treatment option.

    Like

    Reply

Leave a reply to Thyroid Health Cancel reply